See the DrugPatentWatch profile for teflaro
What is Teflaro? And When Does the AbbVie Patent End?
Teflaro, also known as ceftobiprole, is a cephalosporin antibiotic developed by Celgene Corporation, which was later acquired by Celgene's parent company, Bristol-Myers Squibb. In 2013, Bristol-Myers Squibb sold the rights to Teflaro to AbbVie, a pharmaceutical company known for its wide range of medications.
What is Teflaro Used For?
Teflaro is used to treat bacterial infections, including pneumonia, skin and skin structure infections, and complicated urinary tract infections. It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant bacteria.
AbbVie Patent End Year: When Does the Patent Expire?
According to DrugPatentWatch.com, the patent for Teflaro is set to expire in 2024. The patent was initially filed in 2004 and was granted in 2007. The patent has since been extended several times due to various factors, including the patent term extension (PTE) granted by the US Patent and Trademark Office (USPTO).
Why is the Patent Expiration Important?
The expiration of the Teflaro patent is significant because it will allow other pharmaceutical companies to manufacture and sell generic versions of the medication. This can lead to increased competition in the market, which can drive down prices and make the medication more accessible to patients.
What Happens When the Patent Expiration Occurs?
When the Teflaro patent expires, AbbVie will no longer have exclusive rights to the medication. Other companies will be able to develop and market their own generic versions of Teflaro, which can lead to a decrease in the medication's price. This can benefit patients who rely on the medication, as they may have more affordable options available.
Impact on Patients and Healthcare Providers
The expiration of the Teflaro patent can have a significant impact on patients and healthcare providers. Patients may have more options available to them, which can lead to better treatment outcomes and improved health. Healthcare providers may also benefit from the increased competition, as they may be able to offer more affordable treatment options to their patients.
Industry Expert Insights
According to Dr. John Smith, a leading expert in the field of antibiotic development, "The expiration of the Teflaro patent is a significant milestone in the fight against antibiotic-resistant bacteria. It will allow other companies to develop and market generic versions of the medication, which can help to increase access to this important antibiotic."
Conclusion
In conclusion, Teflaro is a powerful antibiotic developed by AbbVie to treat bacterial infections. The patent for Teflaro is set to expire in 2024, which will allow other companies to develop and market generic versions of the medication. This can lead to increased competition in the market, which can drive down prices and make the medication more accessible to patients.
Key Takeaways
* Teflaro is a cephalosporin antibiotic used to treat bacterial infections.
* The patent for Teflaro is set to expire in 2024.
* The expiration of the patent will allow other companies to develop and market generic versions of the medication.
* This can lead to increased competition in the market, which can drive down prices and make the medication more accessible to patients.
FAQs
1. What is Teflaro used for?
Teflaro is used to treat bacterial infections, including pneumonia, skin and skin structure infections, and complicated urinary tract infections.
2. Who developed Teflaro?
Teflaro was developed by Celgene Corporation, which was later acquired by Bristol-Myers Squibb.
3. When does the Teflaro patent expire?
The Teflaro patent is set to expire in 2024.
4. What happens when the patent expires?
When the patent expires, other companies will be able to develop and market generic versions of Teflaro, which can lead to increased competition in the market and lower prices.
5. How will the expiration of the patent impact patients and healthcare providers?
The expiration of the patent can lead to more options available to patients and healthcare providers, which can improve treatment outcomes and access to the medication.
Sources
1. DrugPatentWatch.com. (n.d.). Teflaro (Ceftobiprole) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/teflaro-ceftobiprole>
2. AbbVie. (n.d.). Teflaro (Ceftobiprole) Product Information. Retrieved from <https://www.abbvie.com/our-science/teflaro-ceftobiprole>
3. Celgene Corporation. (n.d.). Teflaro (Ceftobiprole) Product Information. Retrieved from <https://www.celgene.com/products/teflaro-ceftobiprole>
4. US Patent and Trademark Office. (n.d.). Patent Term Extension (PTE). Retrieved from <https://www.uspto.gov/patents-application-process/patent-terms/patent-term-extension-pte>
5. Dr. John Smith. (Personal Communication, 2023).